Key result
Intravenous cibenzoline improved left ventricular diastolic function in HCM patients, with the improvement negatively correlating with the extent of myocardial fibrosis (r = 20.542, P = 0.009).
Why the study?
Does the extent of myocardial fibrosis (LGE) attenuate the effect of intravenous cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy?
Observational (n=22)
Does the extent of myocardial fibrosis (LGE) attenuate the effect of intravenous cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy?
Less extensive myocardial fibrosis on MRI predicts a greater improvement in left ventricular diastolic function following cibenzoline administration in patients with hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Less fibrosis may predict greater cibenzoline diastolic benefit in HCM; hypothesis-generating and requires randomized confirmation.
The aim of this study was to investigate the relationship between late gadolinium enhancement (LGE) and the effect of cibenzoline (CBZ) on left ventricular (LV) diastolic function in hypertrophic cardiomyopathy (HCM) patients. Echocardiography before and after intravenous CBZ (1.4 mg/kg over 5 minutes) and magnetic resonance imaging (MRI) were performed in 22 consecutive patients with HCM [mean age: 65 ± 14 years, obstructive HCM: 14, nonobstructive HCM (HNCM): 8]. The extent of LGE (%LGE = LGE volume/total LV volume) was obtained by contrast-enhanced MRI using custom software. LGE was observed in 19 patients (mean %LGE = 5.1% ± 3.9%). The propagation velocity of LV early filling flow (Vp) increased significantly in patients with obstructive HCM (26 ± 7 to 36 ± 14 cm/s, P = 0.001) and nonobstructive HCM (25 ± 9 to 36 ± 16 cm/s, P = 0.007). A significant negative correlation was observed between the change in Vp and %LGE in patients with HCM (r = 20.542, P = 0.009). Less extensive myocardial fibrosis, as demonstrated by LGE on contrast-enhanced MRI, may predict the ability of CBZ to improve LV diastolic function in HCM.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2010) conducted an observational in Hypertrophic cardiomyopathy (n=22). Cibenzoline vs. Baseline was evaluated on Correlation between change in propagation velocity of left ventricular early filling flow (Vp) and extent of late gadolinium enhancement (%LGE) (r = 20.542, p=0.009). Intravenous cibenzoline improved left ventricular diastolic function in HCM patients, with the improvement negatively correlating with the extent of myocardial fibrosis (r = 20.542, P = 0.009).
Synapse has enriched 10 related papers. Consider them for comparative context: